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S U M M A R Y
Patients with Mendelian susceptibility to mycobacterial diseases (MSMD) mainly suffer from
Mycobacterium and Salmonella infections, which are due to mutations in genes controlling the
interleukin (IL)-12/IL-23-dependent IFN-g production. We performed a molecular diagnosis in two
Mexican patientswith persistentmycobacterial infections. Patients 1 (P1) and 2 (P2) from two unrelated,
non-consanguineous families from two villages near Mexico City developed bacille Calmette–Gue´rin
(BCG) disease secondary to vaccination; patients and their families were studied at the immunological
level for production and response to IFN-g. Theb1 subunit of the IL-12 receptor (encoded by the IL12RB1
gene) was not expressed in cells from P1 or P2, or in two siblings of P1. Sequencing of the IL12RB1 gene
showed the same point mutation 1791+2 T>G, homozygous in patients and heterozygous in parents. P1
and P2 died at the ages of 4 and 16 years, respectively, with disseminated and uncontrolled BCG disease
and with Candida albicans infections in spite of multiple anti-mycobacterial drug treatments. One of P2’s
siblings also died following disseminated mycobacterial infection secondary to BCG vaccination. These
are the ﬁrst cases inMexico of patients with BCG disease traced to amutation in the IL12RB1 gene, with a
fatal outcome. Doctors must be alert to the adverse reactions to BCG vaccination and to persistent
Mycobacterium infections, and in such cases should investigate possiblemutations in the genes of the IL-
12/IL-23–IFN-g axis.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bacille Calmette–Gue´rin (BCG) is a live bacterial vaccine used in
many countries to prevent tuberculosis (TB), with variable
protection. However, because the vaccine consists of live
attenuated bacteria, there is still a risk that inoculation with this
Mycobacterium bovis strain will cause localized (BCGitis) or
disseminated (BCGosis) infection and disease, mainly in indivi-
duals affected with primary immunodeﬁciencies, such as Mende-
lian susceptibility to mycobacterial diseases (MSMD; OMIM* Corresponding author. Tel.: +52 55 5487 0900x2607; fax: +52 55 5573 0487.
E-mail address: spedraza@rocketmail.com (S. Pedraza-Sa´nchez).
1 Both authors contributed equally to this work.
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.005209950, http://www.ncbi.nlm.nih.gov/Omim), who have defects
in some element of the interleukin (IL)-12/IL-23–IFN-g axis.1,2
Genetic defects in components of the said axis are the ultimate
cause of immunological disorders in personswithMSMDandmake
patients prone mainly to infection by low-virulence mycobacteria
such as BCG, environmentalmycobacteria (EM), and non-typhoidal
Salmonella. Since the condition is frequently inherited in an
autosomal recessive fashion, consanguinity in families increases
the likelihood of getting the deleterious defect.3,4
Diverse mutations in six genes (IFNGR1, IFNGR2, IL12B, IL12RB1,
STAT1, and NEMO) controlling the IFN-g-mediated immunity in
humans have been described and associated with the condition
called ‘inborn errors of IL-12- and IFN-g-mediated immunity’,2 a
more inclusive term than MSMD. Allelic heterogeneity in the
six aforementioned genes accounts for 13 known disorders in theses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Geographical location of the families studied. Maps at country, state, and county level show the origin of patients: (1) P1 from San Mateo Atenco (57 440
inhabitants); (2) P2 from Santa Maria Jajalpa (5402 inhabitants). The star represents Toluca (435 125 inhabitants) the State Capital of Estado de Mexico. All data are from the
year 2000 census, INEGI, Mexico; www.inegi.org.mx).
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characteristics, as well as inheritance modes.2,5,6
In this paper, we present two fatal case reports of BCG infection
in two Mexican families. The familial analysis showed a point
mutation in the IL12RB1 gene, causing a complete deﬁciency with
no expression of the IL-12b1 receptor (IL-12Rb1).
2. Case reports
All the studies in the analyzed individuals were done after
obtaining informed consent and were undertaken with the
approval of the local ethics committee.
2.1. Patient 1
Patient 1 (P1) was a female, born to healthy non-consanguine-
ousMestizo parents without a history of TB, in SanMateo Atenco, a
small town near Mexico City (Figure 1). P1 received the complete
immunization schedule, including the BCG vaccine at birth. At the
age of 6 months, she had fever and axillary adenitis with a biopsy
revealing chronic granulomatous lymphadenitis compatible with
TB. A chest X-ray (CXR) was normal and the tuberculin skin test
(TST) negative. Anti-mycobacterial therapy with isoniazid and
rifampin was given for 6 months with a good clinical response. At
the age of 18months, P1 was admitted to the hospital with general
adenopathy, anemia, and a micronodular inﬁltrate on CXR. A new
treatment with isoniazid, rifampin, pyrazinamide, and clarithro-
mycin was given for 2 months, followed by 10 months with
isoniazid plus rifampin, and a clinical improvement was observed.
Four months after stopping the treatment, P1 was admitted to
the hospital with abdominal growth, generalized lymphadenopa-
thy, and suppurative axillary and cervical adenitis. Computed
tomography scans revealed mediastinal lymphadenopathy, hepa-
tosplenomegaly, and multiple abdominal adenitis. A biopsy of the
cervical node showed tuberculous lymphadenitis with abundant
acid-fast bacilli (AFB), resistant to isoniazid and pyrazinamide, and
identiﬁed as Mycobacterium bovis by PCR–restriction fragment
length polymorphism (PCR-RFLP).7,8 Immunological studies werenormal (HIV negative, immunoglobulin levels, lymphocyte sub-
sets, nitroblue tetrazolium (NBT) reduction). P1 had two episodes
of oral candidiasis in 3 months, treated with ﬂuconazole (the ﬁrst
episode was community-acquired and the second presented
during hospitalization); simultaneously to the second thrush
episode, she also had a pulmonary infection and received
amphotericin B. P1 started a new drug treatment (rifampin,
ethambutol, amikacin, and ciproﬂoxacin), with a poor response.
She developed a protein-wasting enteropathy and bilateral pleural
effusion, after which immunological studies of the IL-12/IL-23–
IFN-g axis were initiated. Although a complementary treatment
with recombinant human IFN-g (rhIFN-g; 200mg/m2 three times a
week) was initiated, she died one week later from respiratory
failure. Blood samples from P1 and her parents, and cord blood
from a brother and a sister who were born after P1 died, were
studied. P1’s brother and sister were not vaccinated with BCG and
were reported healthy in September 2009, at the ages of 4 and 2,
respectively.
2.2. Patient 2
Patient 2 (P2)was amale, born in SantaMaria Jajalpa (Figure 1).
Hewas the ﬁrst child born to healthy non-consanguineousMestizo
parents with no history of familial TB. P2 received the BCG vaccine
at the age of 6 months and developed axillary adenopathy, which
resolved spontaneously before he was 1 year old. P2 had an oral
herpes infection and pneumonia successfully treated with anti-
biotics and then remained healthy until he was 10 years old, when
he developed a massive mycobacterial infection with abundant
AFB in the mesenteric lymph nodes. At the time of this infection,
P2’s youngest brother was suffering from BCG disease (patient
P2.1). P2 received isoniazid, rifampin, ethambutol, and clarithro-
mycin for 2 months, and rifampin and isoniazid for an additional
16 months, with symptom remission. When P2 was 13 years old,
he developed a cervical adenopathy and Mycobacterium bovis BCG
was identiﬁed. rhIFN-gwas added to the treatment with rifampin,
isoniazid, clarithromycin, and ciproﬂoxacin (the ﬁrst three were
extended to 14 months). P2 remained asymptomatic and healthy
Figure 2. Functional analysis of the IL-12 receptor in the families studied. IFN-g
production by whole blood samples from P1, P2 and their families stimulated for
24 hwith phytohemagglutinin (PHA) or puriﬁed protein derivative (PPD) alone or in
the presence of rhIL-12 showed no response to this cytokine in the patients.
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when hewas 15 years old and he presented with ﬁstulized cervical
lymphadenitis and abscesses in the thorax; M. bovis was isolated
from the lesions. A new treatment with rifampin, isoniazid,
clarithromycin, and ethambutol plus rhIFN-g was started, which
P2 could take intermittently, not continuously. His clinical
condition deteriorated and ﬁnally the patient died at home at
the age of 16 years and 7 months with candidiasis and pulmonary
and urinary tract infections. No autopsy was performed on the
patient. P2 had two male siblings, both vaccinated with BCG at
birth without adverse reactions; they were both healthy at this
time. P2 had also had another brother who had died at an early age
and whose short clinical history is presented below (P2.1)
2.3. Patient 2.1
P2.1was the youngest of P2’s brothers. He had received the BCG
vaccine at birth and had axillary adenitis at the age of 4 months,
which disseminated to the cervical nodes and whose pathologic
studies were reported as ‘granulomatous adenopathy with
abundant AFB’. He received treatment with isoniazid, rifampin,
and pyrazinamide for 6 months, with remission of symptoms. At
the age of 2 years, P2.1 had suppurative cervical adenopathies,
withMycobacterium sp resistant to pyrazinamide. A new treatment
with isoniazid, rifampin, streptomycin, and ethambutol was given,
with some improvement in the patient. However, at 2 years and 9
months of age he was admitted to the hospital with disseminated
lymphadenitis (draining axillary, cervical, and inguinal nodes), as
well as hepatosplenomegaly. P2.1 received isoniazid, rifampin, and
ethambutol and went home 2 months later in an improved health
condition. However, the patient died at home at age of 3½ years
old. No immunological or genetic studies were performed on P2.1
since he died before we started to study his brother, P2.
2.4. Immunologic and genetic diagnosis
For the two families, immunologic function on IFN-g production
and response was studied in blood cells using methods described
elsewhere.9,10 Peripheral blood cells from P1, P1’s brother and P2
showed low in vitro IFN-g production, which did not increase in
response to IL-12 (Figure 2); the b1 chain of the IL-12 receptor (IL-
12Rb1) was not expressed on T cell blasts or on Epstein–Barr virus
transformed B cells (EBV-B) from these patients (Figure 3). As IL-
12Rb1 was absent in the patient cells, sequencing of the IL12RB1
gene were performed and the same mutation 1791+2 T>G was
found homozygous in patients and heterozygous in parents from
both families (Figures 4 and 5). This mutation at the end of exon 15
and the beginning of intron 16 affects the RNA splicing, which
prevents the synthesis of the polypeptide b1 chain.11
3. Discussion
In this study we demonstrated that an immunological defect in
IFN-g production in the two patients who suffered from
disseminated BCG disease was due to a point mutation in the
IL12RB1 gene. This mutation is responsible for the complete b1
deﬁciency with no expression of the protein on the cell surface.
Immunologic and genetic studies were consistent with a recessive
trait when the probands and their families were analyzed together.
To our knowledge, these are the ﬁrst two cases of BCG disease
associated with an IL-12R mutation reported in Mexican patients.
The infections reported in patients with defects in IL-12
production (in gene IL12B) or its receptor (in gene IL12RB1)
include mostly BCG,1,3,4,9,12–16 EM,17,18 M. tuberculosis,11,13,19,20
and non-typhoidal Salmonella.18,21–23 Sporadic cases with Nocar-
dia,14,24 Kingella kingae,14 cutaneous leukocytoclastic vasculitissecondary to mycobacterial infection,25 leishmaniasis,26 Paracoc-
cidioides brasiliensis,27 and Candida albicans,15,17,28 have also been
observed in other patients. Here, both P1 and P2 had oral
candidiasis at the end of their lives, and the kidney infection that
P2 had before he died was likely due to the dissemination of
Candida infection. However, we do not know if these Candida
infections played a role in the fatal outcomes of the patients
described in this paper. The importance of Candida infections in
patients deﬁcient in IL12Rb1 is now being analyzed by Rodriguez-
Gallego et al. (manuscript in preparation).
Although BCG was not speciﬁcally identiﬁed in P1’s samples
(cultures were reported asM. bovis), her clinical evolution suggests
that the persistent mycobacterial infection was due to BCG
vaccination. In the second family, P2 had BCGitis in his early
childhood, fromwhich he recovered spontaneously; following this
it was only at the age of 10 years that he had a massive abdominal
mycobacterial infection (simultaneously, his younger brother, P2.1
had fatal BCG disease), but the mycobacterial species was not
determined at that time. Four years later M. bovis BCG was
identiﬁed in a cervical lymph node biopsy from P2, indicating the
probable vaccine origin of the infection. Although the mutation
was not determined in P2.1, clinical history and familial
circumstances suggest that he also shared the same mutation.
Therefore, we are facing three fatal cases of BCG disease due to the
same mutation in IL12RB1 in two distinct families, and we do not
Figure 3. The IL-12Rb1 chain is not expressed in the cells frompatients or relatives deﬁcient in IFN-g production. Flow cytometry showed no expression of the IL-12Rb1 chain
in the EBV cell line of P1’s sibling, which was present in the parents (upper panel). IL-12Rb1 was also not expressed in PHA-activated T cells from P2 (lower panel).
Figure 4. Mutation in the IL12RB1 gene. Genomic DNA sequencing of blood cells
from P2 and his family revealed the same point mutation 1791+2 T>G in the
IL12RB1 gene as shown, homozygous for patient and heterozygous in the parents.
The same mutation was found in P1’s family.
Figure 5. Family trees of the two families studied. Circles represent females and
squares males. Genotypes are shown below the symbols. In P2’s family the
mutation would be hypothetical for the two siblings of P2 (P2.1 and P2.2) who died
without proved genetic diagnosis. The probands are indicated with an arrow and
the diagonal line indicates that the subject is dead. No consanguinity is known in
these families. WT = wild type.
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month of unknown causes, also died as a consequence of the
mutation (Figure 5). In 2003, studies in a group of patients with
IL12RB1mutations established low penetrance, favorable outcome,
and amortality rate of 15%;14 at present, the study is being updated
following the analysis of further patients and will probably show a
higher penetrance and mortality (de Beaucoudrey et al.,
manuscript in preparation).
Themutation 1791+2 T>G in the IL12RB1 gene that we found in
our patients has previously been found in Spanish, Iranian and Sri-
Lankan patients suffering fromM. tuberculosis, BCG, and Salmonella
enteritidis infections.11,14 Clinical heterogeneity in symptoms and
outcome have been observed in patients with mutations in the
IL12RB1 gene suffering from BCG disease,4,14 as well as a variable
response to IFN-g treatment.16 The death of P2 in spite of
prolonged but intermittent treatment with several anti-mycobac-
terial drugs plus rhIFN-g suggests that any chance of eliminating
mycobacterial infections in these patients depends on following a
strict and prolonged treatment.
Although the families studied were not aware of any
consanguinity, some degree of familial relationship could exist
between the parents of the patients; even if this is not the case, the
likelihood of the existence of homozygous individuals bymatching
of the mutated genes in small and closed populations is increased
compared to larger communities. The possibility of a founder effect
as the origin of the same mutation in the two unrelated families
needs to be investigated. Searching for candidate clinical cases
withMSMD is suggested for small communities in countrieswhere
BCG is a compulsory vaccine. The timely diagnosis of mutations in
genes controlling the IL-12/IL-23–IFN-g circuit is useful for the
adequate medical care of MSMD patients with infections and as
prophylaxis to avoid BCG vaccination or microbial exposure in
children from affected families.
In summary, the BCG vaccine causes reactions that are
sometimes harmful in a low but non-determined number of
children, and mutations in genes of the IL-12/IL-23–IFN-g axis
must be deﬁnitively investigated in cases of BCG infection and
disease, as well as in infections with EM or non-typhoidal
Salmonella.
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